Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 344,200 shares of Akebia’s common stock on May 31, 2019, including an option to purchase 250,000 shares granted to Dell Faulkingham, Akebia’s newly-hired Senior Vice President, Chief Commercial Officer. The options were granted as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.45 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR Newswire
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
AKBA
Earnings
- 11/7/24 - Miss
AKBA
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- AKBA's page on the SEC website